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ABSTRACT 
Objective: A simple, rapid, accurate and precise stability-indicating UPLC analytical method has been developed and validated for the quantitative 
analysis of Emtricitabine, Tenofovir, Cobicistat and Elvitegravir in bulk drugs and combined dosage forms.  
Methods: ACE C18 (50 mm x 3 mm, 2µ). The column temperature was maintained at 30o
Results: The retention times were observed as 1.46, 3.59, 4.13, 4.64 min for Emtricitabine, Tenofovir disoproxyl fumarate, Cobicistat, and 
Elvitegravir respectively. Linearity ranges were observed 150-275 µg/ml Emtricitabine, 250-375 µg/ml Tenofovir, 100-225 µg/ml Cobicistat and 
100-225 µg/ml Elvitegravir. Relative Standard Deviation did not exceed 2.  
C and run time 8 min. The mobile phase was a mixture of 
Mobile Phase: A–0.1% TFA in Acetonitrile, B–0.1% TFA in Milli-Q-water. The injection volume of samples was 20μl. UV detection was carried out 
using a UV-PDA detector at 240 nm. The validation of this method was done as per ICH guidelines. 
Conclusion: The newly developed UPLC method for separation of different degradation products along with the pure drugs were found to be 
capable of giving faster retention times while still maintaining good resolution than that achieved with conventional HPLC. The decreased flow rate 
0.4 ml/min, in UPLC indicate more economical. This method exhibited an excellent performance in terms of sensitivity and speed. The results of 
stress testing undertaken according to the ICH guidelines reveal that the method is specific and stability-indicating. The proposed method has the 
ability to separate these drugs from their degradation products in tablet dosage forms and hence can be applied to the analysis of routine quality 
control samples and samples obtained from stability studies. 
Keywords: Stability indicating assay, RP-UPLC, Emtricitabine, Tenofovir, Cobicistat, Elvitegravir, Forced degradation studies 




The chemical name of Emtricitabine (EMCB)is 6-(3-Chloro-2-
fluorobenzyl)-1-[(2S)-1 hydroxy-3-methylbutan-2-yl]-7-methoxy-4-
oxo-1, 4-dihydroquinoline-3-carboxylic acid [9] Emtricitabine is the 
(-) enantiomer of a thio analog of cytidine, which differs from other 
cytidine analogs in that it has a fluorine in the 5-position. 
MOA 
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) 
for the treatment of HIV infection in adults [1]. It has a molecular 
formula of C8H10FN3O3
 
S and a molecular weight of 247.25. It has 
the following structural formula:  
 
Fig. 1: Structure of Emtricitabine 
 
It is a white to off-white crystalline powder with a solubility of 
approximately 112 mg per ml in water at 25 °C. 
Tenofovir disoproxil fumarate 
Tenofovir DF (TDF) is a fumaric acid salt of the bis-isopropoxy 
carbonyl oxy methyl ester derivative of tenofovir. The chemical name 
of Tenofovir DF is 9-[(R)-2-[[bis[[(isopropoxy carbonyl)oxy] methoxy] 
phosphinyl] methoxy]propyl] adenine fumarate. 
MOA 
Tenofovir disoproxyl fumarate [2] belongs to a class of antiretroviral 
drugs known as nucleotide analogue reverse transcriptase inhibitors 
(NRTIs). 
It has a molecular formula of C19H30N5O10P • C4H4O4
 
 and a 
molecular weight of 635.51. It has the following structural formula:  
 
Fig. 2: Structure of tenofovir disoproxil fumarate 
 
It is a white to off-white crystalline powder with a solubility of 13.4 
mg per ml in water at 25 °C. All dosages are expressed in terms of 
Tenofovir DF except where otherwise noted. 
Cobicistat 
The chemical name for Cobicistat (COBI2)is 1, 3-Thiazol-5-ylmethyl 
[(2R,5R)-5-{[(2S)-2-[(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl} 
International Journal of Pharmacy and Pharmaceutical Sciences 
ISSN- 0975-1491                 Vol 8, Issue 4, 2016 
Lakshmi et al. 






Cobicistat acts as an HIV integrase inhibitor [3, 4]. 
It has a molecular formula of C40H53N7O5S2
 
 and a molecular weight 
of 776.0. It has the following structural formula:  
 
Fig. 3: Structure of cobicistat 
 
It is adsorbed onto silicon dioxide. Cobicistat on silicon dioxide is a 
white to pale yellow solid with a solubility of 0.1 mg per ml in water 
at 20 °C. 
Elvitegravir 
The chemical name of Elvitegravir (ELVT) is 6-(3-Chloro-2-
fluorobenzyl)-1-[(2S)-1hydroxy-3-methylbutan-2-yl]-7-methoxy-4-
oxo-1, 4-dihydroquinoline-3-carboxylic acid. 
MOA 
Elvitegravir is a drug used for the treatment of HIV infection. It acts 
as an integrase inhibitor [5, 6]. It has a molecular formula of 
C23H23ClFNO5
 
 and a molecular weight of 447.9. Elvitegravir is a 
white to pale yellow powder with a solubility of less than 0.3 
micrograms per ml in water at 20 °C. 
 
Fig. 4: Structure of Elvitegravir 
 
Stribild, a medication to treat HIV-1 infection for treatment-naïve 
adults, has been approved by the Food and Drug Administration 
(FDA). Stribild is a pill combination of four active ingredients-150 
mg of Elvitegravir, 150 mg of Cobicistat, 200 mg of Emtricitabine 
and 300 mg of Tenofovir disoproxil fumarate (equivalent to 245 mg 
of Tenofovir Disoproxil)-and is taken once a day. Stribild is 
commercially available marketed formulation. 
The literature survey revealed that there are very few HPLC and 
spectroscopic [7, 8] methods available for the determination of 
Emtricitabine, Tenofovir disoproxyl fumarate, Cobicistat, 
Elvitegravir in pure and combined dosage forms. The present study 
was aimed to develop a new UPLC method for simultaneous 
estimation of Emtricitabine, Tenofovir disoproxyl fumarate, 
Cobicistat, Elvitegravir in bulk and their combined pharmaceutical 
dosage form using more economical chromatographic conditions. 
MATERIALS AND METHODS 
Drug substance 
Working standards Emtricitabine (99.7%), Tenofovir disoproxyl 
fumarate (99.5%), Cobicistat (99.5%) and Elvitegravir (99.4%) were 
procured from HETERO, Hyderabad, India.  
Instrumentation 
An Agilent-1290, Ultra Performance Liquid Chromatography 
consisting of Binary pump (GA220A), Column compartment 
(G1316C), Autosampler (G4226A), and Diode array detector 
(G4212A), supplied by M/s. Agilent technologies, USA. Mettler-
Toledo analytical balance, model AG-245 capable of weighing 0.01 
mg, supplied by M/s. Mettler AG, Switzerland. Sonicator supplied by 
M/s. Bandelin electronics, Germany. Digital pH meter supplied by 
M/s. Hanna instruments, USA.  
Chemicals and reagents 
HPLC grade Methanol and Acetonitrile were purchased from Merck 
India limited, Mumbai, India. AR grade Trifluoroacetic anhydride, 
supplied by M/s. Sigma-Aldrich, USA. AR grade Hydrochloric acid 
supplied by M/s. Merck, India. GR grade Sodium hydroxide and 
Hydrogen peroxide supplied by M/s. Merck, India. 
Preparation of mobile phase 
Mobile Phase: A–0.1% TFA in Acetonitrile, B–0.1% TFA in Milli-Q-
water. 
Preparation of standard solutions 
Accurately weighed 100 mg of Emtricitabine, 150 mg of Tenofovir, 
75 mg of Cobicistat and 75 mg of Elvitegravir into 50 ml capacity 
standard volumetric flasks. The content in the flask was dissolved 
using methanol and diluted up to the mark with methanol. A 5 ml 
aliquot of each stock solution was transferred into 50 ml volumetric 
flasks and diluted up to the mark using mobile phase. 
Chromatographic conditions 
The mobile phase was a mixture of Mobile Phase: A–0.1% TFA in 
Acetonitrile, B–0.1% TFA in Milli-Q-water. The contents of the 
mobile phase were filtered, before it was used, through 0.45μm 
membrane filter, degassed with a helium sparge for 15 min and 
pumped from the respective solvent reservoirs to the column at a 
flow rate of 0.4 ml/min, ACE C18 (50 mm x 3 mm, 2µ). The column 
temperature was maintained at 30o
 
C and run time 8 min. The 
injection volume of samples was 20μl. UV detection was carried out 
using a UV-PDA detector at 240 nm. The chromatographic 
conditions were shown in table no 1. 
Table 1: Gradient program 
Time (min)  Mobile phase A (%)  Mobile phase B (%) 
0  10  90 
3  90  10 
6  90  10 
6.1  10  90 
8  10  90 
 
Method development 
After no. of trials, optimum chromatographic conditions were fixed 
for better separations. The separate standard calibration lines were 
constructed for each drug. A series of aliquots were prepared from 
the above stock solutions using mobile phase to get the 
concentrations 150-275 µg/ml Emtricitabine, 250-375 µg/ml 
Tenofovir, 100-225 µg/ml Cobicistat and 100-225 µg/ml 
Elvitegravir. Each concentration was injected 6 times into 
chromatographic system. Each time peak area and retention time 
recorded separately for the drugs. Calibration curves were 
constructed by taking average peak area on Y-axis and concentration 
on X-axis separately for all the four drugs. From the calibration 
curves, regression equations were calculated as shown in the fig. No. 
5, 6, 7 & 8. These equations were used for the estimation of drug 
content in their combined tablet dosage form. 
Estimation of pharmaceutical formulation 
For the analysis of drugs, 20 tablets were weighed and triturated in a 
glass mortar and quantity of powder equivalent to 100 mg of 
Lakshmi et al. 
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Emtricitabine, 150 mg of Tenofovir, 75 mg of Cobicistat and 75 mg of 
Elvitegravir into a 50 ml capacity standard volumetric flask and 
dissolved in sufficient quantity of methanol and diluted up to the mark 
with methanol. It was sonicated for 10 min. This solution was then 
filtered through a nylon 0.45 mm membrane filter. From above solution 
5 ml was transferred into 50 ml volumetric flasks. It was further diluted 
with mobile phase to get the required test concentrations of 200 μg/ml 
of EMCB, 300 μg/ml of TDF, 150 μg/ml of COBI and ELVT. This solution 
was injected 6 times into the column, chromatograms and respective 
peak areas were measured. The content of EMCB, TDF, COBI and ELVT 
were calculated by using the regression equation which was indicated as 
% Assay. The results are shown in table 2. 
 
Table 2: Estimation of pharmaceutical formulation 
Drug name Labelled claim (mg) Test concentration  
(μg/ml) 




Emtricitabine 200 200 199.24 99.62 
Tenofovir 300 300 300.06 100.02 
Cobicistat 150 150 149.41 99.60 
Elvitegravir 150 150 150.37 100.24 
 
Method validation 
Validation is defined as establishing documented evidence, which 
provides a high degree of assurance that a specific analytical method 
will consistently produce results meeting its intended analytical 
applications. The method was validated as per ICH guideline. The 
method was validated by performing system suitability, linearity, 
and limit of detection (LOD), limit of quantification (LOQ), precision, 
accuracy, selectivity and robustness. 
Accuracy 
Accuracy was evaluated in triplicate, at three different concentration 
levels equivalent to 50, 100 and 150% of the target concentration of 
active ingredient, by adding a known amount of each of the Standard to a 
pre-analyzed concentration of all drugs (EMCB, TDF, COBI and ELVT) 
and calculating the % of recovery. The results were shown in table 3. 
Precision 
Method precision of the analytical method was determined by analyzing 
six sets of sample solution preparation. Assay of all six replicates sample 
preparations were determined and mean percentage of assay value, 
standard deviation and percentage of relative standard deviation for the 
same were calculated. The results were shown in table 4. 
Precision is the level of repeatability of results as reported between 
samples analyzed on the same day (intra-day) and samples run on 3 
different days (inter-day). To check the intra-day and inter-day 
variation of the method, solution containing 175, 200 & 225 µg/ml 
for Emtricitabine, 275, 300, 325 µg/ml for Tenofovir and 125,150 & 
175 µg/ml for both Cobicistat, Elvitegravir drugs were subjected to 
the proposed UPLC method of analysis and the recoveries obtained 
were noted. The precision of proposed method i.e. the intra and 
inter-day variations in the peak area of the drug solutions were 
calculated in terms of % RSD and the results were presented in the 
table No.4; statistical  results revealed that relative standard 
deviation of drugs at different concentration levels for 6 times was 
less than 2.0. The results are shown in table 5. 
Linearity 
The linearity of the method was determined in the concentration 
range of 150-275μg/ml for Emtricitabine, 250-375μg/ml for 
Tenofovir disoproxyl fumarate, 100-225μg/ml for both Cobicistat & 
Elvitegravir. Each solution was injected six times. The peak area 
versus concentration data was analyzed with least squares linear 
regression. The slope and intercept of the calibration curve were 
reported. The results were shown in table 6, 7. 
  
Table 3: Results of the recovery studies 
Drugs Pre analyzed concentration 
(µg/ml) 






















































Table 4: Method precision 
 S. No. Emtricitabine  Tenofovir  Cobicistat  Elvitegravir 
 200 µg/ml  300 µg/ml   150 µg/ml  150 µg/ml 
1 199.7  297.5  148.0  149.9 
2 201.4  295.6  149.7  147.2 
3 197.8  300.2  149.3  148.4 
4 199.4  298.6  150.8  149.8 
5 199.3  295.0  149.7  149.1 
6 200.1  293.4  150.1  150.2 
Mean 199.4  295.8  149.6  149.1 
Standard Deviation 0.97  1.01  0.79  0.69 
% RSD 0.004  0.003  0.005  0.004 
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Table 5: Results of the intermediate precision studies 
Intra-day Inter-day 






























































Table 6: Calibration data of the proposed method 
Calibration 

















275 3289 375 2714 225 891 225 8974 
250 2950 350 2554 200 789 200 7725 
225 2672 325 2372 175 692 175 6885 
200 2397 300 2182 150 598 150 5905 
175 2086 275 1987 125 490 125 4912 
150 1790 250 1802 100 394 100 3927 
 
Table 7: Optical characteristics of emtricitabine, tenofovir, cobicistat and elvitegravir 
Parameters Emtricitabine   Tenofovir  Cobicistat Elvitegravir 
Linearity range (µg/ml)  150-275  250-375  100-225 100-225 
Regression line equation  y = 11.89x+2.678 y = 7.272x-3.509 y = 39.40x-13.33 y = 39.40x-13.33 
Correlation coefficient (r)   0.999  0.999 0.999 0.999 
LOD (µg/ml) 0.032 0.028 0.059  0.007 
LOQ (µg/ml) 0.10 0.10 0.20 0.02 
 
 
Fig. 5: Calibration curve for Emtricitabine 
 
 
Fig. 6: Calibration curve for Tenofovir 
 
Fig. 7: Calibration curve for Cobicistat 
 
 
Fig. 8: Calibration curve for Elvitegravir 
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LOD and LOQ 
Limit of detection and quantification were established based on the 
signal to noise ratio (S/N) 3:1 and 10:1 respectively. The results 
were shown in table 8. 
 
Table 8: LOD and LOQ 
Active LOD (µg/ml) LOQ (µg/ml) 
Emtricitabine 0.032 0.10 
Tenofovir 0.028 0.10 
Cobicistat 0.059 0.20 
Elvitegravir 0.007 0.02 
 
Robustness 
The robustness of the assay method was established by introducing 
small changes in the chromatographic condition which included the 
percentage of acetonitrile in mobile phase (58% and 62%), flow rate 
(0.38 and 0.42 ml/min) and column oven temperature (25 °C and 35 °C). 
The results were shown in table 9. 
Solution stability 
The solution stability of Emtricitabine, Tenofovir, Cobicistat and 
Elvitegravir in the assay method was carried out by leaving both the 
sample and reference standard solutions in tightly capped 
volumetric flasks at room temperature for 48 h. The same sample 
solution was assayed at 6-hour intervals over the study period. The 
percentage of RSD of the Emtricitabine, Tenofovir, Cobicistat and 
Elvitegravir assay was calculated for solution stability experiments. 
An additional study was carried out using the stock solution by 
storing it in a tightly capped volumetric flask at 4 °C. 
System suitability parameters 
For assessing system suitability, six replicates of working standards 
samples of Emtricitabine, Tenofovir, Cobicistat and Elvitegravir 
were injected and studied the parameters like plate number (N), 
tailing factor (K), resolution, relative retention time and peak 
symmetry of samples. The results were tabulated in table 10. 
 
Table 9: Robustness studies of EMCB, TDF, COBI and ELVT 
Method parameters Conditions Retention Time (RT) 
Emtricitabine Tenofovir Cobicistat Elvitegravir 
Flow Rate+ +0.42 1.43 3.59 4.13 4.60 
Flow Rate- -0.38 1.46 3.59 4.13 4.64 
Organic in Mobile Phase+ +2 % 1.40 3.49 4.10 4.61 
Organic in Mobile Phase- -2 % 1.49 3.52 4.10 4.60 
Column oven temperature- 28 °C 1.41 3.54 4.09 4.59 
column oven temperature+ 32 °C 1.36 3.49 4.10 4.54 
 
Table 10: System suitability parameters 
Parameter Emtricitabine Tenofovir Cobicistat Elvitegravir 
N 6 6 6 6 
Retention time 1.46 3.59 4.13 4.64 
Symmetry 0.99 0.97 1.00 1.04 
Plates 20156 27451 36173 38745 
Resolution - 19.98 6.12 5.68 
Selectivity - 2.46 1.15 1.12 
 
Specificity and selectivity 
Specificity is the degree to which the procedure applies to a single 
analyte and is checked in each analysis by examining blank matrix 
samples for any interfering peaks. The specificity of the method was 
evaluated with regard to interference due to the presence of any 
other placebos. Two different samples were injected and studied 
with respective placebos. The UPLC chromatograms recorded for the 
drug matrix ( a mixture of the drug and placebos) showed almost no 
interfering peaks within retention time ranges. Figure. 5-8 shows 
the respective chromatogram for Emtricitabine, Tenofovir, 
Cobicistat and Elvitegravir with a blank. The fig. shows that the 
selected drugs were cleanly separated. Thus, the UPLC method 
proposed in this study was selective. 
Stress degradation studies 
Preparation of stock solution 
Accurately weighed 100 mg of Emtricitabine, 150 mg of Tenofovir, 
75 mg of Cobicistat and 7 mg of Elvitegravir into 50 ml capacity 
standard volumetric flasks. The content in the flask was dissolved 
using methanol and diluted up to the mark with methanol.  
 
 
Fig. 9: Blank chromatogram 
Lakshmi et al. 




Accurately 5.0 ml aliquot of above stock solution was transferred 
into a 50 ml round bottom flask, and 2.5 ml of 0.1 N HCl was added. 
The flask was refluxed at 60 °C for 30 min using Buchi rota 
evaporator and then allowed to cool. Then neutralized with 0.1N 
NaOH solution. Finally, volume was made up to the mark with 
mobile phase, and percentage of degradation was calculated. 
Alkali degradation 
Accurately 5.0 ml aliquot of above stock solution was transferred 
into a 50 ml round bottom flask, and 2.5 ml of 0.1 N NaOH was 
added. The flask was refluxed at 60 °C for 30 min using Buchi Rota 
evaporator and then allowed to cool. Then neutralized with 0.1N HCl 
solution, finally volume was made up to the mark with mobile phase, 
and percentage of degradation was calculated. 
Peroxide condition 
Accurately 5.0 ml aliquot of above stock solution was transferred 
into a 50 ml volumetric flask, and 3.0 ml of 3% H2O2
Thermal condition 
 was added. The 
flask was kept at room temperature for 30 min then allowed to cool, 
finally volume was made up to the mark with mobile phase, and 
percentage of degradation was calculated. 
200 mg of Emtricitabine, 300 mg of Tenofovir, 150 mg of Cobicistat 
and 150 mg of Elvitegravir were weighed accurately and transfer 
into four different Petri dish and kept in a hot air oven for 8 h at 105 
°C. The samples were then placed in a desiccator till reaches the 
room temperature. From this Petri dish Accurately weighed 100 mg 
of Emtricitabine, 150 mg of Tenofovir, 75 mg of Cobicistat and 75 mg 
of Elvitegravir into 50 ml capacity standard volumetric flasks. The 
content in the flasks was dissolved using methanol and diluted up to 
the mark with methanol. A 5 ml aliquot of each stock solution was 
transferred into 50 ml volumetric flasks and diluted up to the mark 
using mobile phase. 
Photolytic condition 
A 5 ml aliquot of above stock solution was exposed to sunlight for 
about 6hours, and then the sample was diluted with 5 ml of mobile 
phase and percentage of degradation was calculated. 
 
 
Fig. 10: Acid degradation 
 
 
Fig. 11: Alkali degradation 
 
 
Fig. 12: Peroxide condition 
 
 
Fig. 13: Thermal condition 
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Fig. 14: Photolytic condition 
 
Table 11: Results of stress degradation studies 
Stress conditions  Active present after degradation (%) 
Emtricitabine  Tenofovir  Cobicistat  Elvitegravir 
Acid 10.00  59.99  65.65  65.36 
Base 64.77  BDL  64.06  64.83 
Oxidation 98.12  92.67  94.45  90.87 
Thermal 51.58  19.30  89.03  89.50 
Photolytic 63.83  96.09  80.75  80.77 
*BDL = Below Detectable Level 
 
RESULTS AND DISCUSSION 
Optimized chromatographic conditions 
The optimized chromatographic conditions are given in table 1. The 
best peak shape and maximum separation were achieved with mobile 
phase composition of: A–0.1% TFA in Acetonitrile, B–0.1% TFA in 
Milli-Q-water. The best separation, peak symmetry and reproducibility 
were obtained on ACE C18 (50 mm x 3 mm, 2µ). The optimum 
wavelength for detecting the analyte was found to be 240 nm, a flow 
rate of 0.4 ml/min yielded optimum separation and peak symmetry. 
Most of all reported UPLC methods till date use C-8 or C-18 columns. 
Most of this use complex mobile phase compositions. Hence, 
attempts were directed towards the development of a Simple and 
better method on a commonly used C18 column with good 
resolution. Different logical Modifications were tried to get good 
separation among the drugs and the degraded products. These changes 
included a change in mobile phase composition in gradient modes on 
different C18 columns. The results were as shown in table 10. 
Accuracy 
The percentage recovery of Emtricitabine, Tenofovir, Cobicistat and 
Elvitegravir in the combined dosage forms were obtained in a range 
from 99.97% to 101.55%, respectively. Percentage of RSD value of 
replicated sets was less than 2.0 which indicates that this method is 
highly accurate. The results were as shown in table 3. 
 
Table 10: System suitability parameters 
Parameter Emtricitabine Tenofovir Cobicistat Elvitegravir 
N 6 6 6 6 
Retention time 1.46 3.59 4.13 4.64 
Symmetry 0.99 0.97 1.00 1.04 
Plates 20156 27451 36173 38745 
Resolution - 19.98 6.12 5.68 
Selectivity - 2.46 1.15 1.12 
 
Precision 
The precision of the method was determined by repeatability (intraday-
precision) and intermediate precision (Interday-precision) of 
Emtricitabine, Tenofovir, and Cobicistat and Elvitegravir standard 
solution. The obtained results of repeatability (intraday precision) and 
intermediate precision (interday-precision) were less than 2. Percentage 
of RSD value of replicated sets was less than 2.0 which indicates that this 
method is highly precise. The results were as shown in table 5. 
Linearity 
The calibration curve for the Emtricitabine, Tenofovir, Cobicistat 
and Elvitegravir were linear over the concentration range of 150-
275µg/ml, 250-375µg/ml 100-225µg/ml, and 100-225 µg/ml 
respectively. The data for the peak area versus concentration were 
treated by linear regression analysis, and the correlation 
coefficient (r) was obtained (0.999). The regression equation for 
the calibration curve was calculated. The statistical analysis 
revealed that the proposed method was linear the results were as 
shown in table 6, 7. 
LOD and LOQ 
The results of LOD and LOQ data were within the acceptance 
criteria. The signal-to-noise ratio for the LOD and LOQ were well 
within the acceptance criteria. The results were as shown in table 8. 
Robustness 
The robustness of the assay method was established by introducing 
small changes in the chromatographic condition which included the 
percentage of acetonitrile in mobile phase (58% and 62%), flow rate 
(0.38 and 0.42 ml/min) and column oven temperature (28 °C and 32 
°C). The developed method was unaffected by the small deliberated 
changes; it indicated the pro [posed method was robust. The results 
were shown in table 9. 
Degradation studies 
Acid hydrolysis (fig. 10) 
Upon performance of acid degradation studies, 10% of 
Emtricitabine, 59.99% of Tenofovir, 65.65% of Cobicistat and 
65.36% of Elvitegravir active were remaining after degradation. 
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Base hydrolysis (fig. 11) 
Upon performance of base degradation studies, 64.77%, BDL, 
64.06% and 64.83% of Emtricitabine, Tenofovir, Cobicistat and 
Elvitegravir respectively were active present after degradation (%) 
Peroxide hydrolysis (fig. 12) 
Upon performance of peroxide degradation studies, 98.12%, 92.67%, 
94.45% and 90.87% of Emtricitabine, Tenofovir, Cobicistat, and 
Elvitegravir respectively were active present after degradation (%) 
Thermal degradation (fig. 13) 
Upon performance of Thermal degradation studies 51.58%, 
19.30%, 89.03% and 89.50% of Emtricitabine, Tenofovir, 
Cobicistat, and Elvitegravir active were active present after 
degradation (%). 
Photolytic degradation (fig. 14) 
Upon performance of Photolytic degradation 63.83% of 
Emtricitabine, 96.09 % of Tenofovir, 80.75 % of Cobicistat and 80.77 
% of Elvitegravir were active present after degradation (%). 
Results were tabulated in table 11. 
Stability studies 
Emtricitabine degraded more in acid and photolytic condition. Tenofovir 
degraded more in alkali condition. Cobicistat degraded more in acid 
condition. Elvitegravir degraded more in peroxide condition. 
 
Table 11: Results of stress degradation studies 
Stress Conditions  Active present after degradation (%) 
Emtricitabine  Tenofovir  Cobicistat  Elvitegravir 
Acid 10.00  59.99  65.65  65.36 
Base 64.77  BDL  64.06  64.83 
Oxidation 98.12  92.67  94.45  90.87 
Thermal 51.58  19.30  89.03  89.50 
Photolytic 63.83  96.09  80.75  80.77 
*BDL = Below Detectable Level 
 
CONCLUSION 
Stress testing (or forced degradation studies) is an important part of 
drug development process, and the pharmaceutical industry has 
much interest in this area. A simple, rapid, accurate and precise 
stability-indicating UPLC analytical method has been developed and 
validated for the quantitative analysis of Emtricitabine, Tenofovir, 
Cobicistat and Elvitegravir in bulk drugs and combined dosage 
forms. The newly developed UPLC method for separation of 
different degradation products along with the pure drugs was found 
to be capable of giving faster retention times while still maintaining 
good resolution than that achieved with conventional HPLC. The 
decreased flow rate 0.4 ml/min, in UPLC indicate more economical. 
This method exhibited an excellent performance in terms of sensitivity 
and speed. The results of stress testing undertaken according to the 
ICH guidelines reveal that the method is specific and stability-
indicating. The proposed method has the ability to separate these 
drugs from their degradation products in tablet dosage forms and 
hence can be applied to the analysis of routine quality control samples 
and samples obtained from stability studies. 
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